denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: Newly Diagnosed Multiple Myeloma: Many Choices and More Questions
Hematology Disease Topics & Pathways:
Combination therapy, Antibody Therapy, Bispecific Antibody Therapy, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Lymphoid Malignancies
Disclosures: Kumar: Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncopeptides: Other: Independent review committee participation; Roche: Research Funding; Sanofi: Research Funding; MedImmune/AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding.
See more of: Education Program